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-/- -/-BACKGROUND & AIMS: Innate lymphoid cells (ILCs) are a
heterogeneous group of mucosal inﬂammatory cells that
participate in chronic intestinal inﬂammation. We investigated
the role of interleukin 6 (IL6) in inducing activation of ILCs in
mice and in human beings with chronic intestinal inﬂammation.
METHODS: ILCs were isolated from colons of Tbx21-/- 
Rag2-/- mice (TRUC), which develop colitis; patients with in-
ﬂammatory bowel disease (IBD); and patients without colon
inﬂammation (controls). ILCs were characterized by ﬂow
cytometry; cytokine production was measured by enzyme-
linked immunosorbent assay and cytokine bead arrays. Mice
were given intraperitoneal injections of depleting (CD4, CD90),
neutralizing (IL6), or control antibodies. Isolated colon tissues
were analyzed by histology, explant organ culture, and cell
culture. Bacterial DNA was extracted from mouse fecal samples
to assess the intestinal microbiota. RESULTS: IL17A- and IL22-
producing, natural cytotoxicity receptor–negative, ILC3 were
the major subset of ILCs detected in colons of TRUC mice.
Combinations of IL23 and IL1a induced production of cyto-
kines by these cells, which increased further after administra-
tion of IL6. Antibodies against IL6 reduced colitis in TRUC mice
without signiﬁcantly affecting the structure of their intestinal
microbiota. Addition of IL6 increased production of IL17A,
IL22, and interferon-g by human intestinal CD3-negative, IL7-
receptor–positive cells, in a dose-dependent manner. CON-
CLUSIONS: IL6 contributes to activation of colonic natural
cytotoxicity receptor–negative, CD4-negative, ILC3s in mice
with chronic intestinal inﬂammation (TRUC mice) by increasing
IL23- and IL1a-induced production of IL17A and IL22. This
pathway might be targeted to treat patients with IBD because
IL6, which is highly produced in colonic tissue by some IBD
patients, also increased the production of IL17A, IL22, and
interferon-g by cultured human colon CD3-negative, IL7-
receptor–positive cells.Tbx21 Rag2 ulcerative colitis; UC, ulcerative colitis.
© 2015 by the AGA Institute
0016-5085
http://dx.doi.org/10.1053/j.gastro.2015.04.017
Open access under CC BY license.Keywords: UC; CD; Innate Immunity; Immune Regulation.nﬂammatory bowel disease (IBD), comprising Crohn’sIdisease (CD) and ulcerative colitis (UC), is an
increasingly common immune-mediated disease of the gut
of unknown cause.1,2 The genetic architecture of IBD is
complex, with more than 130 signiﬁcantly associated sus-
ceptibility loci identiﬁed to date,3 indicating that multiple
mechanisms of disease may exist. Nevertheless, prominent
roles for innate immunity and particular immune response
pathways, including the interleukin (IL) 23/IL17 axis,
strongly are implicated.
Innate lymphoid cells (ILCs) are emerging as important
players in mucosal immunity. Although recognized to
perform protective roles against mucosal pathogens,4,5 they
also contribute to chronic intestinal inﬂammation, which is
particularly apparent in mice lacking conventional T and B
cells.6,7 This is in part dependent on their capacity to pro-
duce inﬂammatory cytokines, including interferon-g, IL17A,
and IL22.4–8 ILCs can be subdivided into discrete pop-
ulations, which accumulate in mucosal tissues in different
pathologic settings.9 At least 3 subsets exist, including ILC1s,
which produce interferon-g; ILC2s, which produce IL5/
IL13; and ILC3, which can be subdivided further based on
differential expression of natural cytotoxicity receptors
(NCRs), CD4, and production of IL17 and/or IL22.9
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neously develop severe colitis with striking similarities to
some aspects of human UC.10 Colon lesions histologically
resemble UC with goblet cell depletion, crypt abscess for-
mation, epithelial hyperplasia, and inﬁltration of colonic
lamina propria with neutrophils and mononuclear cells.7,10
TRUC mice develop inﬂammation-associated epithelial
dysplasia, which frequently progresses to frank adenocar-
cinoma,11 one of the most severe complications in human
forms of IBD. TRUC disease is dependent on interactions
between intestinal CD11cþ mononuclear phagocytes and
CD90þ IL7R-receptor–positive (IL7Rþ) ILCs.7 Depletion of
ILCs or genetic deﬁciency of the common g-chain cytokine
receptor, which is necessary for ILC survival, prevents dis-
ease.7 Similarly, blockade of IL23 or IL17A signiﬁcantly at-
tenuates disease.7 ILCs accumulate in gut lesions from IBD
patients12–14 and it has been speculated that targeting these
cells might represent a viable therapeutic approach in IBD.15
IL236,7 and IL1b16 contribute to ILC activation, although
curiously TRUC mice that additionally are deﬁcient for
either IL23R or IL1R are not fully protected from colitis,17
consistent with a possible role for alternative ILC activa-
tion pathways contributing to disease. The purpose of this
study was to investigate the proximal signals responsible for
driving intestinal ILC activation and to determine whether
similar pathways might exist in human disease.
Materials and Methods
Mice
Balb/C Rag2-/- and wild-type mice were sourced commer-
cially (Jackson Laboratories; Bar Harbor, ME). TRUC mice were
a gift from Laurie Glimcher. Animal experiments were per-
formed in accredited facilities in accordance with the UK Ani-
mals (Scientiﬁc Procedures) Act 1986 (Home Ofﬁce License
Number PPL: 70/6792 and PPL: 70/7869 from November
2013).
Human Studies
Studies in human tissues received ethical approval from the
City and Hackney Local Research Ethics Committee (REC
reference: 10/H0704/74 and 10/H0804/65). Colonic lamina
propria mononuclear cells (cLPMCs) were isolated as described
previously18 from colectomy specimens and endoscopically
acquired biopsy specimens. Normal colonic mucosal samples
were collected from macroscopically unaffected areas of pa-
tients undergoing intestinal resection for colon cancer or
polyps. Informed written consent was obtained in all cases.
Flow Cytometry and Cell Sorting
Intracellular cytokine expression was measured as
described previously.7 Cells were stimulated with IL23 (10–20
ng/mL), IL6 (10–100 ng/mL), or phorbol 12-myristate 13-
acetate (PMA) (50 ng/mL) and ionomycin (1 mmol/L) for 4–6
hours at 37C with monensin (3 mmol/L) added for the last 2
hours. In human work, antibodies used to stain cell surface
antigens were incubated with unstimulated cells for 25 minutes
and then ﬁxed in 2% paraformaldehyde pending analysis.
For ﬂuorescence-activated cell sorter puriﬁcation of murineILCs, CD45þ cells ﬁrst were sorted immunomagnetically from
unfractionated cLPMCs using anti-CD45 beads (Miltenyi) and
LS columns (Miltenyi). CD45þ cells were stained with CD90,
NKp46, and IL7R. Antibodies used in ﬂow cytometry experi-
ments are listed in Supplementary Table 1.
Ex Vivo Organ Culture
Colon explants cultures from murine experiments were
performed as described previously.7 Three biopsy punches
from the distal colon were cultured in 500 mL of complete
medium for 24 hours at 37C. In human studies explant cul-
tures were set up as described previously.18 Cytokine produc-
tion in culture supernatants was measured by enzyme-linked
immunosorbent assay (ELISA).
Cell Culture
Unfractionated murine splenocytes (2  106/mL) and
mesenteric lymph node (mLN) cells (1  106/mL) or cLPMCs
(1  106/mL) were cultured in complete medium for 24 hours
at 37C as described previously.7 cLPMCs from IBD and
noninﬂammatory control patients were cultured with recom-
binant human IL6 (R&D) (0–100 ng/mL) overnight at 37C, 5%
CO2, and then restimulated with PMA (50 ng/mL) and ion-
omycin (1 mmol/L). In some experiments, cLPMCs were
cultured with IL6 (100 ng/mL) for 6 hours in the presence of
monensin (3 mmol/L). Fluorescence-activated cell sorter–puri-
ﬁed NCR- ILC3s (CD45þ CD90þ IL7Rþ NKp46-) from TRUC mice
were cultured at 5  104/mL for 24 hours. Cytokine concen-
trations in culture supernatants were measured by ELISA (R&D
Systems and eBioscience).
Histology
Colon histology was processed, stained (H&E), and colitis
scores were calculated as described previously.7 Proximal and
distal colitis scores from individual mice were averaged, unless
otherwise stated.
ELISA and Cytokine Bead Arrays
Cytokine concentrations were measured in culture super-
natants by ELISA or T-helper cell (Th)1, Th2, or Th17 CBA (BD
Biosciences).
Microarray and Real-Time Polymerase
Chain Reaction
RNA was extracted from 3 Rag2-/- and 3 TRUC mice, aged
10 weeks, using TRIzol reagent (Invitrogen Carlsbad, CA).
Transcript expression was analyzed with Mouse Genome 430
2.0 Affymetrix Expression Array. For real-time polymerase
chain reaction (PCR) experiments cells were lysed in TRIzol
reagent (Invitrogen) and RNA was extracted. Complementary
DNA was generated with the complementary DNA synthesis kit
(Bioline, Taunton, MA). Quantitative PCR was used to quantify
messenger RNA transcripts using TaqMan gene expression as-
says (Applied Biosystems). Gene expression was normalized to
the expression of b-actin to generate DCT values and relative
abundance was quantiﬁed using the 2-DCT method. Human
RORC (Hs01076112_m1) and b-actin (4326315E) TaqMan
quantitative PCR primer sets were used.
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Intraperitoneal injections of anti-CD4 (1 mg, GK1.5), anti-
CD90 (1 mg, 30H12), anti-IL6 (750 mg, MP5-20F3), or
isotype-matched control antibodies (LTF-2 or HRPN) (Bio X
Cell, West Lebanon, NH) were administered on days 0, 7, 14, 21,
and 28 (anti-CD4, anti-CD90) or days 0, 4, 9, 14, 18, 23, and 27
(anti-IL6).
Microbiota Analysis
See the Supplementary Materials and Methods section for
more detail.
Results
NCR- CD4- ILC3 Cells Are the Predominant
Colonic ILC Subset in Chronic Intestinal
Inﬂammation in TRUC Mice
We validated the phenotype of ILCs in TRUC mice,
conﬁrming excessive accumulation of IL17A- and IL22-
producing CD90þ IL7Rþ NCR- ILC3 in diseased colons
(Figure 1A and 1B, Supplementary Figure 1A–D). CD4-
expressing NCR- ILC3s resembling lymphoid tissue
inducer cells participate in mucosal immune responses in
the gut,5 therefore, we considered the possibility that CD4þ
ILCs might be the NCR- ILC3 subset responsible for medi-
ating chronic inﬂammation in TRUC mice. CD4þ cells were
present in mLNs of TRUC mice (many of which
co-expressed CD90); however, very few CD4þ cells were
present in the colon (Figure 1C). Given the low frequency
of intestinal CD4þ ILCs in TRUC mice we considered it
unlikely that these cells would play a major role in disease.
To test this assumption we depleted CD4-expressing cells
in vivo. The administration of anti-CD4 antibodies suc-
cessfully depleted CD4-expressing cells in mLNs and colon
of TRUC mice (Figure 1C). However, many CD90þ cells still
remained in the colon and there was no reduction in the
number of IL17A- or IL22-producing cells (Figure 1D).
Depleting anti-CD4 treatment did not alter the severity of
TRUC disease signiﬁcantly (Figure 1E). In contrast, anti-
CD90 treatment depleted both CD90- and CD4-expressing
ILCs, reduced the number of IL17- and IL22-producing
cells in the colon, and signiﬁcantly attenuated disease
(Figure 1C–E). Taken together, these data indicate
IL17A/IL22 producing CD90þ IL7Rþ NCR- CD4- ILC3 are
the key ILC population in the colon responsible for causing
disease in TRUC mice.
IL6 Is Expressed Highly and Augments
Pathogenic Cytokine Production in TRUC Mice
We sought to deﬁne the proximal immune signals
responsible for triggering effector function of colonic NCR-
ILC3 in TRUC mice. IL1b and IL6 were among the most
highly expressed (>2-fold induction) cytokine transcripts in
the colon of TRUC mice in comparison with Rag2-/- mice
(Figure 2A). The other IL1 family member, Il1a, and the IL23
subunit transcripts (Il23a and Il12b) also were increased.
Proximal cytokines responsible for driving ILC1 (IL12, IL15,
and IL18) or ILC2 (IL25 and IL33) responses were notup-regulated, and, indeed in most instances were down-
regulated in the colon of TRUC mice in comparison with
Rag2-/- controls.
IL23 and IL1 have been described to play an important
role triggering ILCs in TRUC disease, therefore, in this study
we focussed our attention on IL6. In addition to increased
Il6 transcripts in the colon, there were very high concen-
trations of IL6 in serum and signiﬁcantly increased pro-
duction of IL6 in colon explant cultures from TRUC mice
(Supplementary Figure 2A). Transcripts of genes known to
be regulated by IL619 were up-regulated in the colon of
TRUC mice in comparison with Rag2-/- controls
(Supplementary Figure 2B), including well-recognized im-
mune genes (Socs1, Socs3, and Icam1), IL6 signaling com-
ponents (Stat1 and Stat3), and anti-apoptotic genes (Bcl3,
Bcl6, and Bcl-x1). The most highly expressed IL6-regulated
gene in the colon of TRUC mice (12-fold enrichment) was
Pou2af1, which encodes a transcriptional co-activator
responsible for IL6-mediated regulation of IL17 responses
in T cells.20
To determine whether IL6 might trigger ILC-derived cyto-
kines we stimulated unfractionated cLPMCs and mLN cells
fromTRUCmicewith recombinant IL6. Strikingly, IL6 triggered
IL17A production by both cLPMCs and mLN cells (Figure 2B).
We also performed ﬂow cytometry with intracellular cytokine
staining after IL6 stimulation of unfractionated mLN cells.
Although less potent than IL23, IL6 induced expression of
IL17A in NCR- ILC3s (Figure 2C). To determine whether this
was a cell-intrinsic phenomenon we puriﬁed CD90þ IL7Rþ
NCR- ILC3s from TRUC colons by ﬂuorescence-activated cell
sorting (Supplementary Figure 3A). To our surprise, neither
IL6, IL23, nor IL1a by themselves induced signiﬁcant cytokine
production by puriﬁed colonic NCR- ILC3s (Figure 2D). How-
ever, the combination of IL23 and IL1awas a potent trigger for
ILC production of IL17A and IL22. The addition of IL6 together
with IL23 and IL1awas the most potent trigger of all. Puriﬁed
intestinal NCR- ILCs from TRUC mice produced little tumor
necrosis factor a or interferon-g under these conditions
(Supplementary Figure3B). IL23and IL1awereweak inducers
of IL6 by colonic NCR- ILCs (Supplementary Figure 3B). Taken
together, these data showed that IL6 augments IL23/IL1a-
induced pathogenic cytokine production by intestinal ILCs in
TRUC mice in a cell-intrinsic manner.
IL6 signals through a heterodimeric receptor comprising
ubiquitously expressed gp130 and selectively expressed
IL6Ra. However, IL6Ra also exists as a soluble form, which
can complex with IL6 in solution and then bind to cells
expressing gp130, enabling cells, which do not usually ex-
press IL6Ra, to respond to IL6 stimulation. Therefore, we
investigated IL6Ra and soluble IL6Ra (sIL6Ra) expression
in TRUC mice. IL6Ra expression by ILCs was highly variable
in the colon of TRUC mice, but typically was less than 10%
(Supplementary Figure 4A, and data not shown). However,
sIL6Ra was abundant in the serum of TRUC mice and was
detected in supernatants from cultured colon explants and
unfractionated splenocytes (Supplementary Figure 4B).
Therefore, it is likely that ILCs respond to IL6 stimulation
directly, but also potentially through trans-signaling given
the abundance of sIL6R in TRUC mice.
Figure 1. IL17A/IL22-
producing CD4- NCR-
ILC3 mediate colitis in
TRUC mice. (A) Flow
cytometry dot plots of live,
CD45þ cells according to
expression of CD90 and
IL7R in the colons of
Rag2-/- and TRUC mice,
and (B) absolute numbers
of live CD45þ CD90þ
IL7Rþ ILCs in the colons of
TRUC and Rag2-/- mice.
Each dot/square repre-
sents an individual mouse.
Line depicts the median.
(C) Representative ﬂow
cytometry dot plots (left)
and statistical analysis
(right) of the proportion of
CD4þ and CD90þ cells
(gated on live CD45þ cells)
in mLNs and colons of
TRUC mice treated with
isotype-matched control
antibodies (n ¼ 5), anti-
CD4 (n ¼ 4), or anti-CD90
(n ¼ 4) antibodies. Statis-
tical analyses were per-
formed on colonic cells
and show the proportion of
colonic ILCs (cILCs) after
treatment. *P < .019, **P <
.04. (D) Representative
ﬂow cytometry dot plots
(left) and statistical anal-
ysis (right) of the propor-
tion of IL17Aþ and IL22þ
cells (gated on live CD45þ
cells) in the colon of TRUC
mice treated with isotype-
matched control anti-
bodies (n ¼ 5), anti-CD4
(n ¼ 4), or anti-CD90 (n ¼
24) antibodies. Cells were
stimulated with PMA and
ionomycin before intracel-
lular cytokine staining *P <
.01. (E) Representative
colon micrographs (H&E
stained) (left) and statisti-
cal analysis of colitis
scores (right) of TRUC
mice treated with isotype-
matched control anti-
bodies, anti-CD4, or anti-
CD90 antibodies. *P <
.03 (for both anti-CD90 vs
control antibody and anti-
CD90 vs anti-CD4). Each
dot/square represents an
individual mouse. Lines
depict the median.
August 2015 IL6 Increases Cytokines by ILCs 459
BA
SI
C
AN
D
TR
AN
SL
AT
IO
NA
L
AT
Figure 2. IL6 promotes cytokine production by
NCR- ILC3s in a cell-intrinsic manner. (A) Microarray
analysis showing an abundance of cytokine tran-
scripts in the colon of TRUC mice relative to Rag2-/-
mice. Blue dotted line depicts 2-fold induction. (B)
IL17A production by unfractionated cLPMCs and
mLN cells isolated from TRUC mice in medium
alone (-) or after supplementation with recombinant
IL6 or IL23. Columns represent mean cytokines and
error bars depict SEM. Analysis of cLPMCs
comprised 4 biological replicates. Analysis of mLN
included 9 biological replicates for the unstimulated
condition and 7 biological replicates for each of the
stimulated conditions. *P < .02; **P < .003. (C) Flow
cytometry plots of intracellular IL17A expression by
CD90þ NKp46- cells after stimulation of unfractio-
nated mLN cells with IL6, IL23, or unstimulated cells
(-), which were incubated with monensin alone.
Data are representative of 3 separate experiments.
(D) Cytokine production by ﬂuorescence-activated
cell sorted CD45þ CD90þ IL7Rþ NKp46- ILCs
puriﬁed from the colons of TRUC mice (the gating
strategy for cell sorting is illustrated in
Supplementary Figure 3A). Puriﬁed NCR- ILCs were
stimulated with combinations of IL1a, IL6, and IL23
as depicted. After 24 hours cytokine concentrations
were measured in culture supernatant by ELISA or
CBA. Data are representative of 2 individual ex-
periments with ILCs pooled from 10–15 colons.
Bars show the mean cytokine production and error
bars depict SEM.
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Independently of Changes to Intestinal
Microbiota Community Proﬁles
To determine whether IL6-mediated activation of innate
immunity was functionally important in TRUC disease, mice
were treated with monoclonal antibodies that neutralize the
biological activity of IL6. Treatment with anti-IL6 resulted in
loss of IL6 bioavailability (Supplementary Figure 5A). IL17A
production by unfractionated cLPMCs and splenocytes was
reduced signiﬁcantly in anti-IL6–treated TRUC mice,
although was not abolished completely (Figure 3A). IL6
neutralization signiﬁcantly attenuated TRUC disease,
including reduced colitis scores and reduced splenomegaly
(Figure 3B and C).
Similar to the situation in human IBD, TRUC disease is
associated with perturbation of intestinal microbial com-
munities. Because IL6 directly inﬂuences the success of
mucosal colonization by some intestinal bacteria,21 we
considered the possibility that attenuation of chronic TRUC
disease after IL6 blockade might have occurred secondarily
to changes in key components in the composition of the
intestinal microbiota. To address this question we
sequenced 16S ribosomal RNA genes that were PCR-
ampliﬁed from fecal samples from anti-IL6 or control anti-
body–treated TRUC mice. Overall, we identiﬁed 2642
different operational taxonomic units (OTUs). Treatment
with anti-IL6 antibody appeared to have a relatively minor
impact on the microbiota (Figure 4A). At the phylum level,
Firmicutes were reduced slightly in proportional abundance
in anti-IL6–treated mice (P ¼ .035) (Figure 4A) but, at ﬁner
taxonomic levels, anti-IL6 treatment did not impact the
proportional abundance of the most common 150 OTUs
signiﬁcantly, which cumulatively accounted for more than
96% of the total amount of sequence data generated
(Supplementary Table 2). Cluster analysis, using the Bray
Curtis calculator, conﬁrmed that there was no signature
microbiota proﬁle associated with anti-IL6 treatment
(Supplementary Figure 5B). Helicobacter typhlonius was
ubiquitously present in anti-IL6– or isotype control–treated
mice, however, the proportional abundance did not differ
signiﬁcantly between the 2 groups either before or after
treatment (Figure 4B). There was a tendency for increased
bacterial diversity in the gut of anti-IL6–treated mice in
comparison with control antibody–treated mice, although
this did not achieve statistical signiﬁcance (P < .095)
(Supplementary Figure 5C).
IL6 Augments Pathogenic Cytokine Production
by Colonic CD3- IL7Rþ Cells From IBD Patients
Our preclinical data support the possibility that targeting
IL6 may be therapeutically tractable in chronic gut inﬂam-
mation. Therefore, we aimed to verify whether this pathway
was relevant in human disease. As expected, stimulation of
unfractionated intestinal immune cells with PMA and ion-
omycin resulted in production of pathogenic cytokines,
including IL17A, IL22, and interferon-g by CD3þ T cells
(Figure 5A and Supplementary Figure 6A). However, we also
observed production of these cytokines in the non–T-cell(CD3-) fraction, particularly in IBD patients. Within the
non–T-cell fraction (CD3-), we could identify a population of
IL7R-expressing cells in the colon of patients with CD, UC,
and noninﬂammatory control patients (Figure 5B). Although
the frequency of these cells was variable, their proportional
abundance within the lymphocyte population was increased
in IBD patients in comparison with noninﬂammatory con-
trols (Figure 5B). Consistent with ILC3s being present
among the CD3- IL7Rþ population, there was enriched
expression of RORgt and c-kit (CD117) (Figure 5C and
Supplementary Figure 6C). RORC transcripts also were
enriched in ﬂuorescence-activated cell sorter–puriﬁed CD3-
IL7Rþ cells analyzed by real-time PCR (Supplementary
Figure 6B), corroborating the likelihood of ILCs being pre-
sent in the CD3- IL7Rþ population. Analysis of the CD3-
IL7Rþ population according to NCR expression showed the
presence of 3 discrete populations, comprising NKp46þ
NKp44- cells, NKp44þ NKp46- cells, and NCR- (NKp44-
NKp46-) cells (Figure 5D and Supplementary Figure 6C),
indicating that NCRþ and NCR- ILCs are present within this
CD3- IL7Rþ population. In most patients, including IBD and
noninﬂammatory control patients, CD3- IL7Rþ NKp44þ
NKp46- cells were the predominant subset present
(Figure 5D and Supplementary Figure 6C).
To determine whether CD3- IL7Rþ cells present in
diseased mucosa of IBD patients were responsive to IL6,
cLPMCs were incubated overnight with recombinant human
IL6 before being restimulated with PMA and ionomycin.
Production of IL17A, IL22, and interferon-g by CD3- IL7Rþ
cells was increased signiﬁcantly when cLPMCs were
cultured in the presence of IL6 (Figure 6A and B). In addi-
tion, some samples were stimulated with IL6 directly
without mitogen, which showed induction of IL17A by CD3-
IL7Rþ cells in a dose-dependent manner (Figure 6C).
Finally, we analyzed IL6 production by diseased mucosa
from IBD patients to see whether blocking IL6 might be a
reasonable therapeutic strategy in some or all IBD patients.
IL6 was produced by colon explant cultures in CD, UC, and
noninﬂammatory control patients (Supplementary
Figure 6D). However, IL6 production was variable, espe-
cially in IBD patients, ranging from 72.2 to 8426.4 pg/mg
colonic tissue. IBD patients could be stratiﬁed according to
mucosal production of IL6, with half of IBD patients pro-
ducing relatively low levels comparable with noninﬂam-
matory control patients and the other half producing high
amounts (>1000 pg/mg tissue). Taken together, these data
indicate that IL6, which is produced in very high quantities
in approximately 50% of CD and UC patients drives patho-
logically relevant immune pathways in chronic intestinal
inﬂammation.Discussion
CD4- NCR- ILC3s are the predominant CD90þ IL7Rþ ILC
population in the colon of TRUC mice responsible for
causing disease. Puriﬁed intestinal NCR- ILC3 from TRUC
mice produced IL17A and IL22, but were poor producers of
interferon-g and tumor necrosis factor a. They were also a
modest source of IL6. Few NCRþ ILCs were present in the
Figure 3. IL6 blockade reduces
IL17A production and attenu-
ates TRUC disease. (A) IL17A
concentration in culture super-
natants of unfractionated
cLPMCs and splenocytes from
TRUC mice treated with anti-IL6
(n ¼ 8) or isotype-matched
control antibodies (n ¼ 8). (B)
Representative colon micro-
graphs (H&E stained) (left panel)
and statistical analysis (right
panel) of colitis scores of distal
colons of TRUC mice treated
with anti-IL6 or isotype-
matched control antibodies. (C)
Spleen and colon mass of
TRUC mice treated with anti-IL6
or isotype-matched control an-
tibodies. Each dot/square rep-
resents an individual mouse.
Lines represent medians. Re-
sults from 2 separate antibody
blockade experiments con-
ducted under the same experi-
mental conditions were pooled.
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Figure 4. IL6 blockade does not signiﬁcantly impact the
composition of the intestinal microbiota in TRUC mice. (A)
The mean percentage of sequences of particular phyla pre-
sent in the intestinal microbiota of TRUC mice before (top
panel) and after (bottom panel) treatment with anti-IL6 (red
bars) or isotype-matched control antibodies (white bars). (B)
The mean proportional abundance of H typhlonius in the in-
testinal microbiota of TRUC mice before and after treatment
with anti-IL6 (red bars) or isotype-matched control antibodies
(white bars). Error bars depict the SEM.
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reporting a requirement for T-bet in NKp46þ ILC develop-
ment and differentiation.22 Intestinal CD4þ ILCs are
important in host resistance to intestinal pathogens, such as
Citrobacter rodentium.5 Here, we show that CD4þ ILCs,
which are abundant in mLN, but infrequent in the colon, do
not play a major role in TRUC disease. Depletion of CD4þ
ILCs had no impact on pathogenic cytokine production or
disease outcome.
In TRUC mice, highly puriﬁed colonic NCR- ILC3 did not
respond to IL23 or IL1a in isolation. Instead, combinations
of IL23 together with IL1a were required for production of
effector cytokines by ILC3. Furthermore, additional expo-
sure to IL6 was required for optimal IL17A and IL22 pro-
duction, showing a novel role for IL6 in the innate immune
system in chronic intestinal inﬂammation.
IL17A-, IL22-, and interferon-g–producing CD3- IL7Rþ
cells also were identiﬁed in the colonic lamina propria of
patients with IBD. Although this population is heteroge-
neous, there was enrichment of RORgt and c-kit, conﬁrming
the likelihood that ILC3 were present within this compart-
ment. Most CD3- IL7Rþ cells were NKp44þ, although
NKp46þ and NCR- (NKp44- NKp46-) cells also were present.
These data are broadly consistent with previous reports of
ILC populations in human gut.12–14 Crucially, IL6 increased
pathogenic cytokine production by CD3- IL7Rþ cLPMCs
from IBD patients in a dose-dependent manner, consistent
with our preclinical data showing IL6-responsive colonic
ILC3s.
IL6 is a pleiotropic cytokine that may be important in
IBD. Peripheral blood and cLPMCs produce excess IL6 in
IBD,23,24 often at levels correlating with disease activity.25
Genetic variation at the IL6 locus is linked with early onset
IBD26 and polymorphisms at loci encoding IL6R signaling
components are associated with increased IBD risk.3 IL6
blockade is therapeutic in some preclinical models of
IBD, although it has been assumed that the therapeutic
mechanism likely was attributable to limitation of
T-cell–mediated pathology27–30 because IL6 contributes to
intestinal Th17 differentiation.31 We show a novel role of
IL6 in innate immune-mediated chronic intestinal pathol-
ogy. It is interesting that cytokines contributing to CD4þ
Th17 differentiation, including IL1, IL23, and IL6, have
conserved roles promoting innate IL17 production. Our
data build on other work implicating ILCs as potentially
important mediators in IBD,12–14 and conﬁrm NCR- ILC3
as a source of pathogenic cytokines in IBD. Polymorphisms
at multiple susceptibility loci in IBD that previously were
considered to impact adaptive immunity, similarly could
impact ILC phenotype, including RORC, IL23R, IL12RB2,
IL12B, IL22, IFNG, STAT1, STAT3, STAT4, CCR6, IL1R1,
IL15RA, and IL6ST.3 Accordingly, it is possible that genetic
variation at these loci in IBD could impact disease sus-
ceptibility by altering the activation and effector function
of mucosal ILCs. However, the relative contribution of ILC
to the initiation and propagation of chronic intestinal
inﬂammation in IBD remains to be determined. Polyclonal
stimulus of unfractionated cLPMCs from IBD patients
showed that most cytokine-expressing cells reside within
Figure 5. CD3- IL7Rþ cells are
expanded in IBD patients. (A) Flow
cytometry plots showing CD3 and
intracellular IL17A expression in
unfractionated cLPMCs after stimu-
lation with PMA and ionomycin.
Additional representative ﬂow
cytometry plots are illustrated in
Supplementary Figure 6A. (B)
Representative ﬂow cytometry plots
(left panel) and statistical analysis
(right panel) of CD3 and IL7R stain-
ing by LPMCs in the colon of
noninﬂammatory control and IBD
patients. Individual dots represent
individual patients. *P < .04. (C)
Flow cytometric analysis of the
phenotype of colonic CD3- IL7Rþ
cells. Grey histograms show isotype
control antibody staining. White
histograms show staining with spe-
ciﬁc antibody. Data are representa-
tive of more than 3 independent
experiments in IBD patients. (D)
Flow cytometry dot plots showing
expression of NKp46 and NKp44 by
colonic CD3- IL7Rþ cells in nonin-
ﬂammatory control and IBD pa-
tients. Further analyses of additional
patient replicates are shown in
Supplementary Figure 6C and D.
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Figure 6. IL6-responsive CD3- IL7Rþ cells are present in the
colon of IBD patients. (A) Flow cytometry histograms and (B)
statistical analyses of intracellular cytokine expression by
CD3- IL7Rþ cells after overnight culture in the presence or
absence of IL6 (100 ng/mL). Cells were restimulated with
PMA and ionomycin before staining. (B) Each connected pair
of dots represents an individual patient. (C) Flow cytometry
histograms showing the number of CD3- IL7Rþ IL17Aþ cells
after culture with increasing doses of IL6.
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cytokine responses induced by polyclonal stimuli may
overestimate T-cell contribution because under physio-
logical conditions few of these tissue-trafﬁcking T cells
would be encountering their relevant antigen, so would
unlikely be triggered to produce cytokine. By contrast,
despite their numeric inferiority to T cells, mucosal ILC
are likely to be activated directly by cytokine signals
abundant in chronically inﬂamed tissue, such as IL6. IL6-induced stimulation of ILC effector function may prove
to be especially pertinent in UC because IL23, the canon-
ical ILC-activating cytokine, is produced at low levels in UC
in comparison with CD.32
In this study, IL6 neutralization reduced innate pro-
duction of IL17A in TRUC mice and signiﬁcantly attenuated
disease severity, although the magnitude of impact was less
than seen with ILC depletion or IL23 blockade.7 This is in
keeping with our observation that although IL6 is required
for optimal activation of ILC effector function, other prox-
imal cytokine signals, including IL23 and/or IL1 stimulation,
additionally are required. IL6 blockade had a minimal
impact on the intestinal microbiota, other than a minor shift
in the proportional abundance of Firmicutes and a tendency
for increased intestinal bacterial diversity. It is possible that
this latter change occurred secondary to reduced intestinal
inﬂammation in anti-IL6–treated mice. Indeed, IBD activity/
severity is recognized to correlate inversely with bacterial
diversity in the gut.33,34
Our data support extending biological therapies targeting
IL6 in IBD. The IL6R blocking antibody tocilizumab is efﬁca-
cious in other inﬂammatory diseases, including arthritis35,36
and lupus,37 and a pilot study in CD showed promising
initial results.38 In this study mucosal IL6 production was
highly variable, however, only half of IBD patients produced
more IL6 than non-IBD control patients. Similarly, the fre-
quency of CD3- IL7Rþ cells, and themagnitude of IL6-induced
cytokine responses by these cells alsomarkedly was variable.
With the promise of personalized medicine on the horizon,39
it is tempting to speculate that treatment strategies targeting
IL6 might be favored in patient subsets deﬁned by high
mucosal expression of IL6 and/or high frequencies of IL6
responsive effector cells in diseased tissue.
In summary, we have shown that IL6 augments patho-
genic cytokine production by intestinal ILCs in chronic in-
testinal inﬂammation and that this pathway may be
operational in human IBD. Novel therapeutic strategies
targeting ILC or their proximal cytokine signals may offer a
new treatment paradigm in IBD.
Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dx.doi.org/10.1053/
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Supplementary Materials and Methods
Microbiota Analysis
DNA was extracted from mouse fecal samples using the
FastDNA SPIN Kit for Soil and a FastPrep 24 machine (MP
Biomedicals Santa Ana, CA) according to the protocol provided
by the manufacturer. Bacterial 16S ribosomal RNA genes were
PCR-ampliﬁed using barcoded primers MiSeq 27F (5’AAT
GATACGGCGACCACCGAGATCTACACTATGGTAATTCCAGMGT
TYGATYMTGGCTCAG-3’) and MiSeq-338R (5’-CAAGCAGAA
GACGGCATACGAGAT-barcode-AGTCAGTCAGAAGCTGCCTCCC
GTAGGAGT-3’), which target variable regions V1–V2 of the
16S ribosomal RNA gene. Q5 Taq polymerase (New England
Biolabs, Ipswich, MA) was used for the PCR step, and 4 PCR
reactions were performed per sample. Cycling conditions
were as follows: 98C for 2 minutes, followed by 20 cycles of
98C for 30 seconds, 50C for 30 seconds, 72C for 90 sec-
onds, and then a ﬁnal extension step at 72C for 5 minutes.
The 4 PCR reactions from each DNA extraction then
were pooled and concentrated down to 25 mL volumes per
sample. PCR amplicons then were quantiﬁed using a Qubit
2.0 Fluorometer (Life Technologies, Ltd, Carlsbad, CA) and
equimolar concentrations of each were added to a ﬁnal
mastermix for sequencing, using an Illumina MiSeq (San
Diego, CA) machine with 2  250 bp read length. Sequence
data have been deposited in the European Nucleotide
Archive under Study Accession Number ERP005850 and
Sample Accession numbers ERS459682–ERS459702.
The sequence data were processed by following the
MiSeq SOP of the mothur software package (Available at:
http://www.mothur.org/wiki/MiSeq_SOP).1 Paired-read
contigs were created from the forward and reverse read
sequence data, and preliminary quality processing was
performed by removing all contigs that were shorter than
260 bp, longer than 450 bp, or those that contained any
ambiguous bases or homopolymeric stretches longer than 7
bases. Perseus,2 as implemented in mothur, was used to
remove putative chimeras, and any reads mapping to chlo-
roplasts, mitochondria, eukarya, or archaea also were
removed. After these steps, more than 486,000 sequences
were left in the ﬁnal data set (range, 447–51,571 sequences
per sample). Next, after a preclustering step (diffs, 3), 97%
similarity OTUs were generated. Taxonomic classiﬁcations
for each of these OTUs were created using the RDP taxon-
omy provided at the mothur web page. Metastats,3 as
implemented in mothur, was used to test for signiﬁcant
differences in the proportional abundance of each of the
phyla present, and the 150 most abundant OTUs between
anti-IL6 and control mice. Bacterial diversity was measured
by generating Shannon and inverse Simpson indices in
mothur. Before these calculations each sample was sub-
sampled randomly down to 447 reads to ensure equal
sequencing depth for each. Kruskall–Wallis and Mann–
Whitney U tests, implemented in Minitab v16, were used to
test for signiﬁcant differences in diversity measures be-
tween the anti-IL6 and control mouse groups. A cluster
dendrogram, using the Bray Curtis calculator, also was
generated in mothur from the subsampled data set, and
subsequently was visualized using the iTOL online software
resource.4
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Supplementary Table 1.Flow Cytometry Antibodies Used
Antigen Clone Supplier
Anti-mouse antibodies
CD45 30-F11 eBioscience
CD90.2 53-2.1 eBioscience
CD127 A7R34 eBioscience
NKp46 29A1.4 eBioscience
CD126 D7715A7 Biolegend
CCR6 140706 R&D Systems
ICOS 7E.17G9 eBioscience
CD4 RM4.5 eBioscience
Hematopoietic lineage cocktail
(CD3, CD45R, B220, CD11b, TER-119, Gr-1)
17A2, RA3-6B2, M1/70, TER-119 eBioscience
CD62L MEL-14 eBioscience
IL17RB 752101 R&D Systems
CD69 H1.2F3 eBioscience
RORgt AFKJS-9 eBioscience
IL17A eBio17B7 eBioscience
IL22 1H8PWSR eBioscience
Interferon-g XMG1.2 eBioscience
IL4 11B11 eBioscience
Anti-human antibodies
CD3 UCHT-1 Biolegend
CD127 A019D5 (eBioRDR5) Biolegend (eBioscience)
CD117 104D2 eBioscience
NKp46 9E2 eBioscience
NKp44 44.189 eBioscience
IL17RB I170220 R&D Systems
RORgt AFKJS-9 eBioscience
IL17A eBio64DEC17 eBioscience
IL22 22URTI eBioscience
Interferon-g 4S.B3 eBioscience
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Supplementary Table 2.Metastats Comparison Between the Proportional Abundance of the Top 150 Most Abundant OTUs in the Microbiota Data Set Between Anti-IL6
and Control Mice Groups
OTU no.
RDP taxonomic classiﬁcations
NCBI MegaBLAST ID P value Q valuePhylum Class Order Family Genus
Otu0001 Firmicutes(100) Bacilli(100) Lactobacillales(100) Lactobacillaceae(100) Lactobacillus(100) Lactobacillus animalis/murinus .287595 1
Otu0002 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) unclassiﬁed(100) Butyrivibrio species P79 (86%
similarity)
.022376 1
Otu0003 Firmicutes(100) Bacilli(100) Lactobacillales(100) Lactobacillaceae(100) Lactobacillus(100) Lactobacillus taiwanensis/
johnsonii/acidophilus
.947484 1
Otu0004 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVb(100) Clostridium lactatifermentans
(90% similarity)
.15343 1
Otu0005 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Eubacterium plexicaudatum
(92% similarity)
.82004 1
Otu0006 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Unclassiﬁed(100) Unclassiﬁed(100) Butyricimonas species JCM
18677 (80% similarity)
.012182 1
Otu0007 Proteobacteria(100) Epsilonproteobacteria(100) Campylobacterales(100) Helicobacteraceae(100) Helicobacter(100) Helicobacter typhlonius .173889 1
Otu0008 Deferribacteres(100) Deferribacteres(100) Deferribacterales(100) Deferribacteraceae(100) Mucispirillum(100) Mucispirillum colimuris .063365 1
Otu0009 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) Alistipes onderdonkii (90%
similarity)
.874014 1
Otu0010 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) Alistipes senegalensis (91%
similarity)
.800781 1
Otu0011 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) Clostridium scindens (88%
similarity)
.766219 1
Otu0012 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Coprococcus catus (88%
similarity)
.571687 1
Otu0013 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) Oscillibacter valericigenes
(91% similarity)
.03155 1
Otu0014 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Bacteroidaceae(100) Bacteroides(100) Bacteroides acidofaciens/
uniformis
.082054 1
Otu0015 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) Anaerotruncus colihominis
(92% similarity)
.489023 1
Otu0016 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Clostridium hathewayi (92%
similarity)
.861923 1
Otu0017 Firmicutes(100) Bacilli(100) Lactobacillales(100) Lactobacillaceae(100) Lactobacillus(100) Lactobacillus reuteri .644746 1
Otu0018 Proteobacteria(100) Deltaproteobacteria(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Desulfocurvus vexinensis
(87% similarity)
.44467 1
Otu0019 Deferribacteres(100) Deferribacteres(100) Deferribacterales(100) Deferribacteraceae(100) Mucispirillum(100) Mucispirillum colimuris (97%
similarity)
.039672 1
Otu0020 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Unclassiﬁed(99) Unclassiﬁed(99) Tannerella forsythensis (82%
similarity)
.262652 1
Otu0021 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Bacteroidaceae(100) Bacteroides(100) Bacteroides acidifaciens .733786 1
Otu0022 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Prevotellaceae(100) Paraprevotella(100) Prevotella species (87%
similarity)
.137208 1
Otu0023 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(52) Unclassiﬁed(52) Coprococcus catus (84%
similarity)
.501202 1
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Supplementary Table 2.Continued
OTU no.
RDP taxonomic classiﬁcations
NCBI MegaBLAST ID P value Q valuePhylum Class Order Family Genus
Otu0024 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Pseudobutyrivibrio ruminis
(88% similarity)
.510185 1
Otu0025 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Paludibacter(77) Prevotella dentalis (81%
similarity)
.162484 1
Otu0026 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Bacteroidaceae(100) Bacteroides(100) Bacteroides uniformis (96%
similarity)
.195279 1
Otu0027 Firmicutes(100) Erysipelotrichia(99) Erysipelotrichales(99) Erysipelotrichaceae(99) Erysipelotrichaceae_
incertae_sedis(99)
Eubacterium cylindroides
(88% similarity)
.605205 1
Otu0028 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) Clostridium aminophilum (86%
similarity)
.246769 1
Otu0029 TM7(100) TM7_class_incertae_
sedis(100)
TM7_order_incertae_
sedis(100)
TM7_family_incertae_
sedis(100)
TM7_genus_incertae_
sedis(100)
TM7 phylum species (93%
similarity)
.222701 1
Otu0030 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Clostridium phytofermentans
(90% similarity)
.574396 1
Otu0031 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Clostridium celerecrescens
(93% similarity)
.664006 1
Otu0032 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) Clostridium scindens (84%
similarity)
.737231 1
Otu0033 Proteobacteria(100) Gammaproteobacteria(100) Enterobacteriales(100) Enterobacteriaceae(100) Unclassiﬁed Escherichia/Enterobacter/
Citrobacter/Shigella
species
.497501 1
Otu0034 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) Alistipes senegalensis (92%
similarity)
.127302 1
Otu0035 Firmicutes(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Segmented ﬁlamentous
bacterium
.798342 1
Otu0036 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) Eubacterium oxidoreducens
(87%)
.334068 1
Otu0037 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .263709 1
Otu0038 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Unclassiﬁed(100) Unclassiﬁed(100) .951701 1
Otu0039 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Bacteroidaceae(100) Bacteroides(100) .178105 1
Otu0040 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Lachnospiracea_incertae_
sedis(79)
.987598 1
Otu0041 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .948299 1
Otu0042 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Bacteroidaceae(100) Bacteroides(100) .334148 1
Otu0043 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Dorea(93) .850598 1
Otu0044 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .622208 1
Otu0045 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .948849 1
Otu0046 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) .211071 1
Otu0047 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVb(100) .449205 1
Otu0048 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) .101219 1
Otu0049 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Butyricicoccus(100) .597761 1
Otu0050 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Odoribacter(100) .824846 1
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Otu0051 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(72) .889006 1
Otu0052 Bacteroidetes(100) Unclassiﬁed(99) Unclassiﬁed(99) Unclassiﬁed(99) Unclassiﬁed(99) .352835 1
Otu0053 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .420749 1
Otu0054 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .807154 1
Otu0055 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Roseburia(100) .549208 1
Otu0056 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) unclassiﬁed(100) .795695 1
Otu0057 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Acetanaerobacterium(100) .795544 1
Otu0058 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .594923 1
Otu0059 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .319484 1
Otu0060 Firmicutes(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) .815476 1
Otu0061 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) .245678 1
Otu0062 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Roseburia(100) .642752 1
Otu0063 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .866248 1
Otu0064 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) .684305 1
Otu0065 Actinobacteria(100) Actinobacteria(100) Coriobacteriales(100) Coriobacteriaceae(100) Enterorhabdus(100) .470026 1
Otu0066 Firmicutes(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) .781442 1
Otu0067 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .075425 1
Otu0068 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .23604 1
Otu0069 Proteobacteria(100) Deltaproteobacteria(100) Desulfovibrionales(100) Desulfovibrionaceae(100) Desulfovibrio(93) .122282 1
Otu0070 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Dorea(100) .335755 1
Otu0071 Firmicutes(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) .275564 1
Otu0072 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Unclassiﬁed(100) .6759 1
Otu0073 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(98) Unclassiﬁed(98) .739009 1
Otu0074 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .099638 1
Otu0075 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Unclassiﬁed(100) .142259 1
Otu0076 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .446379 1
Otu0077 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Butyrivibrio(91) .048125 1
Otu0078 Actinobacteria(100) Actinobacteria(100) Coriobacteriales(100) Coriobacteriaceae(100) Unclassiﬁed(100) .020051 1
Otu0079 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .995336 1
Otu0080 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Dorea(100) .580909 1
Otu0081 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Butyrivibrio(96) .231131 1
Otu0082 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .144752 1
Otu0083 Actinobacteria(100) Actinobacteria(100) Coriobacteriales(100) Coriobacteriaceae(100) Asaccharobacter(100) .683732 1
Otu0084 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .059598 1
Otu0085 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .557724 1
Otu0086 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .829296 1
Otu0087 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Unclassiﬁed(100) .147604 1
Otu0088 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .325188 1
Otu0089 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .270353 1
Otu0090 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVa(98) .893607 1
Otu0091 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Unclassiﬁed(97) Unclassiﬁed(97) .064746 1
Otu0092 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Syntrophococcus(100) .465783 1
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Otu0093 Proteobacteria(100) Deltaproteobacteria(100) Desulfovibrionales(100) Desulfovibrionaceae(100) Desulfocurvus(73) .719197 1
Otu0094 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Pseudoﬂavonifractor(100) .223923 1
Otu0095 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Pseudoﬂavonifractor(65) .323615 1
Otu0096 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .220402 1
Otu0097 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .755524 1
Otu0098 Firmicutes(100) Erysipelotrichia(100) Erysipelotrichales(100) Erysipelotrichaceae(100) Clostridium_XVIII(100) .167966 1
Otu0099 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .658952 1
Otu0100 Firmicutes(100) Bacilli(100) Lactobacillales(100) Streptococcaceae(100) Streptococcus(100) .271556 1
Otu0101 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .529912 1
Otu0102 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Unclassiﬁed(98) .239692 1
Otu0103 Actinobacteria(100) Actinobacteria(100) Coriobacteriales(100) Coriobacteriaceae(100) Unclassiﬁed(100) .438692 1
Otu0104 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Flavonifractor(97) .884299 1
Otu0105 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Parabacteroides(100) .604151 1
Otu0106 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .052835 1
Otu0107 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Lactonifactor(100) .688385 1
Otu0108 Firmicutes(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) .808444 1
Otu0109 Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) Unclassiﬁed(100) .580963 1
Otu0110 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) .590556 1
Otu0111 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .70702 1
Otu0112 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .629385 1
Otu0113 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVa(97) .690915 1
Otu0114 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .659852 1
Otu0115 Firmicutes(100) Clostridia(100) Clostridiales(100) Unclassiﬁed(100) Unclassiﬁed(100) .052071 1
Otu0116 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Clostridium_IV(100) .496749 1
Otu0117 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Lachnospiracea_incertae_
sedis(64)
.783083 1
Otu0118 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .450217 1
Otu0119 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .474766 1
Otu0120 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Roseburia(100) .677578 1
Otu0121 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Pseudoﬂavonifractor(100) .764818 1
Otu0122 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Roseburia(71) .221575 1
Otu0123 Proteobacteria(100) Deltaproteobacteria(100) Desulfovibrionales(100) Desulfovibrionaceae(100) Bilophila(100) .759601 1
Otu0124 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Hydrogenoanaero-
bacterium(100)
.641479 1
Otu0125 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Pseudoﬂavonifractor(100) .015658 1
Otu0126 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Flavonifractor(100) .017547 1
Otu0127 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Butyrivibrio(100) .106234 1
Otu0128 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .090769 1
Otu0129 Firmicutes(100) Erysipelotrichia(100) Erysipelotrichales(100) Erysipelotrichaceae(100) Erysipelotrichaceae_
incertae_sedis(100)
.304972 1
Otu0130 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Syntrophococcus(100) .351336 1
Otu0131 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Flavonifractor(100) .733134 1
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Otu0132 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Pseudoﬂavonifractor(100) .651459 1
Otu0133 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .336219 1
Otu0134 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) .364453 1
Otu0135 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .297057 1
Otu0136 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Anaerotruncus(100) .255234 1
Otu0137 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(66) .06594 1
Otu0138 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVa(100) .934883 1
Otu0139 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(100) Unclassiﬁed(100) .364453 1
Otu0140 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .019222 1
Otu0141 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .486003 1
Otu0142 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .714399 1
Otu0143 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .641689 1
Otu0144 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Porphyromonadaceae(69) Unclassiﬁed(69) .511826 1
Otu0145 Bacteroidetes(100) Flavobacteria(97) Flavobacteriales(97) Unclassiﬁed(97) Unclassiﬁed(97) .718342 1
Otu0146 Bacteroidetes(100) Bacteroidia(100) Bacteroidales(100) Rikenellaceae(100) Alistipes(100) .977493 1
Otu0147 Firmicutes(100) Clostridia(100) Clostridiales(100) Ruminococcaceae(100) Oscillibacter(100) .345778 1
Otu0148 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .08833 1
Otu0149 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Clostridium_XlVb(100) .548781 1
Otu0150 Firmicutes(100) Clostridia(100) Clostridiales(100) Lachnospiraceae(100) Unclassiﬁed(100) .633538 1
NOTE. Taxonomic classiﬁcations for each OTU were generated using the reference taxonomy database from the Ribosomal Database Project. The numbers in parenthesis
following each classiﬁcation show the consistency of the classiﬁcation assignments (in percent) for all of the sequence reads within a given OTU. p values and q values
(false discovery rate adjusted p values, to allow for multiple comparisons) were generated using Metastats software (White JR et al. PLoS Comput Biol. 2009:e1000352).
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Supplementary Figure 1. (A) Representative ﬂow cytometry plot and statistical analysis (B) showing differential expression of
NKp46 and CCR6 in live CD45þ CD90þ IL7Rþ cells in the colon of Rag2-/- (n ¼ 6, white bar) and TRUC (n ¼ 5, red bar) mice.
Error bars depict SEM. *P < .01, **P < .005. (C) Flow cytometric analysis of the phenotype of CD90þ IL7Rþ ILCs in the colons
of TRUC mice. Grey histograms show staining with isotype-matched control antibody in comparison with staining with speciﬁc
antibody (white histograms with black lines). Data are representative of more than 3 individual experiments. (D) Proportion of
cytokine-expressing CD45þ CD90þ IL7Rþ ILCs in the colons of Rag2-/- and TRUC mice after stimulation of unfractionated
cLPMCs with PMA and ionomycin. Each dot/square represents an individual mouse.
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Supplementary Figure 2. (A) IL6 concentration in serum (left panel) and colon explant culture (right panel) of Rag2-/- and TRUC
mice measured by ELISA. Dots/squares represent individual mice. Line depicts the median. (B) Microarray analysis showing
abundance of transcripts encoded by genes known to be regulated by IL6 in the colon of TRUC mice relative to Rag2-/- mice.
Blue bars represent transcripts up-regulated in the colons of TRUC mice and red bars represent down-regulated genes (in
comparison with Rag2-/- mice).
467.e9 Powell et al Gastroenterology Vol. 149, No. 2
Supplementary Figure 3. (A) FACs gating strategy used to purify ILCs from the colon of TRUC mice. CD45þ cells were ﬁrst
enriched from cLPMCs using anti-CD45 immunomagnetic beads. ILCs were FACs puriﬁed more than 98%. (B) Cytokine
production by FACs puriﬁed CD90þ IL7Rþ NKp46- colonic ILCs from TRUC mice. Cells were cultured in the presence of
combinations of IL1a, IL23, IL6 (as depicted), or medium alone (unstimulated). IL6 was measured in culture supernatant by
CBA. Bars show the mean cytokine production and error bars depict the SEM. Data are from 2 independent experiments.
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Supplementary Figure 4. (A) Flow cytometry plots showing IL6R expression by CD4þ T cells, ILCs (lineage- IL7Rþ) in the
colons of wild-type (WT) and TRUC mice. Data are representative of 3 independent experiments. (B) Concentration of sIL6R in
serum (n ¼ 6) and supernatants of cultured colon explants (n ¼ 5) and unfractionated splenocytes (n ¼ 3) measured by ELISA.
Bars represent the mean sIL6R concentration and error bars depict the SEM.
467.e11 Powell et al Gastroenterology Vol. 149, No. 2
August 2015 IL6 Increases Cytokines by ILCs 467.e12
=
Supplementary Figure 5. (A) Concentration of IL6 in serum of TRUC mice treated with anti-IL6 or control isotype antibody.
Dots/squares represent individual mice. Line depicts median. (B) Bray Curtis cluster dendrogram showing that anti-IL6
treatment is not associated with a distinct microbiota proﬁle. “Pre” indicates samples before anti-IL6 treatment and “Post”
indicates samples after treatment. Bacterial families colored in shades of green belong to the Firmicutes phylum, blue belong
to the Bacteroidetes phylum, yellow belong to the Deferribacteres phylum (Mucispirillum genus), and maroon/red belong to the
Proteobacteria phylum. (C) Box and whisker plots of Simpson diversity index of the intestinal microbiota from TRUC mice
treated with anti-IL6 or isotype-matched control antibodies. Diversity indices are highly sensitive to differential sequencing
depth. Therefore, analyses were conﬁned to 477 reads per sample.
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Supplementary Figure 6. (A) Representative ﬂow cytometry plots of intracellular cytokine and surface CD3 expression in
noninﬂammatory control, CD, and UC patients. Cells were stimulated with PMA and ionomycin. (B) Real-time PCR analysis of
RORC expression in sorted colonic CD3- IL7Rþ cells in comparison with CD14þ monocytes (immunomagnetically selected
from peripheral blood monocytes). Histogram shows the mean expression of RORC in puriﬁed colonic CD3- IL7Rþ cells (n ¼ 2
IBD patients) relative to monocytes. (C) Proportion of colonic CD3- IL7Rþ cells expressing c-kit (CD117) in noninﬂammatory
control, CD, and UC patients. (D) Proportion of colonic CD3- IL7Rþ cells expressing NKp46, NKp44, or double-negative cells
(NKp46- NKp44-) in noninﬂammatory control, CD, and UC patients. (E) IL6 production in colon explant cultures from IBD
patients. In graphs, each dot represents an individual patient and a line depicts the median.
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Supplementary Figure 6. (Continued)
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